- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05328024
Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma (IPRICE)
June 4, 2026 updated by: Centre Paul Strauss
This project aims to organise the sampling of blood and tumor at key points of the standard of care of patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (HNSCC).
This will allow to identify new potential predictive biomarkers of efficacy of immunotherapy and to investigate the evolution of the tumoral microenvironment after successive systemic treatments.
Study Overview
Detailed Description
Tumor and blood samples will be collected on patients treated by anti-PD1 immunotherapy at different timepoints.
Tumor samples will be collected (i) before initiation of immunotherapy, (ii) at 50 days after initiation of immunotherapy and, optionally, in case of disease progression, (iii) before the initiation of the new line of chemotherapy and (iv) at 50 days after initiation of chemotherapy.
Blood samples will be collected : (i) before initiation of immunotherapy, (ii) at each cycles of treatment until 84 days after initiation of immunotherapy and, optionally, in case of disease progression, (iii) before the initiation of the new line of chemotherapy and (iv) at each cycle until 50 days after initiation of chemotherapy (maximum 2 samples per month).
Study Type
Observational
Enrollment (Estimated)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Manon VOEGELIN
- Phone Number: 03 68 33 95 23
- Email: promotion-rc@icans.eu
Study Contact Backup
- Name: Valérie SARTORI
- Phone Number: 03 68 33 95 23
- Email: promotion-rc@icans.eu
Study Locations
-
-
France
-
Strasbourg, France, France, 67033
- Recruiting
- Institut de cancérologie Strasbourg Europe
-
Principal Investigator:
- Mickaël BURGY
-
Contact:
- Mickaël BURGY
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck not amenable to local therapy and/or with metastatic disease and with an indication to treatment by anti-PD1 immunotherapy
Description
Inclusion Criteria:
- Patients with recurrent squamous-cell carcinoma of the head and neck not amenable to local therapy and/or with metastatic disease
- Tumor directly accessible to clinical examination (tumor of oral cavity and of oropharynx) and/or cervical lymphadenopathy accessible to echography allowing to realise biopsy under local anesthesia
- Indication to treatment by anti-PD1 immunotherapy according to French competent authority recommendations
- Performance status 0, 1 or 2
- At least one measurable lesion on RECIST V1.1 criteria
Exclusion Criteria:
- Head and neck squamous cell carcinoma accessible to a local treatment
- Cancer of nasopharynx, sinus or nasal cavity
- Other histology than epidermoid
- Patients with contraindication for anti-PD1 immunotherapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Recurrent and/or metastatic head and neck carcinoma
Patients with indication of anti-PD1 immunotherapy according to recommendations
|
anti-PD1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
prospective validation of the expression of interferon-gamma signature to predict anti-PD1 immunotherapy response.
Time Frame: at 3 months after initiation of immunotherapy
|
objective response according to RECIST v1.1 (response evaluation criteria in solid tumours)
|
at 3 months after initiation of immunotherapy
|
|
prospective validation of the expression of interferon-gamma signature to predict anti-PD1 immunotherapy response.
Time Frame: at 3 months after initiation of immunotherapy
|
objective response according to iRECIST criteria (immune response evaluation criteria in solid tumours)
|
at 3 months after initiation of immunotherapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prospective validation of the expression of interferon-gamma signature to predict progression free survival.
Time Frame: at 3 years after inclusion
|
Time from date of inclusion to the event of tumor recurrence or clinical progression or radiological progression on primary tumor or on lymph nodes or on metastasis or death whatever the cause.
|
at 3 years after inclusion
|
|
Prospective validation of the expression of interferon-gamma signature to predict overall survival.
Time Frame: at 3 years after inclusion
|
Time from date of inclusion to death whatever the cause.
|
at 3 years after inclusion
|
|
Prospective validation of the expression of interferon-gamma signature to predict duration of objective response.
Time Frame: at 3 years after inclusion
|
Time from date of first observation of objective response to progressive disease according to RECIST v1.1 or death..
|
at 3 years after inclusion
|
|
Exploratory outcome : investigation of the expression of other molecular signatures such as immune cells panel within the tumor microenvironment to predict anti-PD1 immunotherapy response.
Time Frame: at 3 months after initiation of immunotherapy
|
objective response according to RECIST v1.1
|
at 3 months after initiation of immunotherapy
|
|
Exploratory outcome : investigation of the expression of other molecular signatures such as immune checkpoints protein expression level to predict anti-PD1 immunotherapy response.
Time Frame: at 3 months after initiation of immunotherapy
|
objective response according to RECIST v1.1
|
at 3 months after initiation of immunotherapy
|
|
Exploratory outcome : investigation of the expression of other molecular signatures such as biomarkers expression level involved in immunogenic cell death and in mitophagy to predict anti-PD1 immunotherapy response.
Time Frame: at 3 months after initiation of immunotherapy
|
objective response according to RECIST v1.1
|
at 3 months after initiation of immunotherapy
|
|
Exploratory outcome : investigation of the expression of other molecular signatures such as protein expression level involved in hypoxia to predict anti-PD1 immunotherapy response.
Time Frame: at 3 months after initiation of immunotherapy
|
objective response according to RECIST v1.1
|
at 3 months after initiation of immunotherapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 25, 2023
Primary Completion (Estimated)
August 25, 2029
Study Completion (Estimated)
August 25, 2029
Study Registration Dates
First Submitted
April 7, 2022
First Submitted That Met QC Criteria
April 7, 2022
First Posted (Actual)
April 14, 2022
Study Record Updates
Last Update Posted (Actual)
June 5, 2026
Last Update Submitted That Met QC Criteria
June 4, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.